389 related articles for article (PubMed ID: 33686177)
1. Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity.
Mandrup OA; Ong SC; Lykkemark S; Dinesen A; Rudnik-Jansen I; Dagnæs-Hansen NF; Andersen JT; Alvarez-Vallina L; Howard KA
Commun Biol; 2021 Mar; 4(1):310. PubMed ID: 33686177
[TBL] [Abstract][Full Text] [Related]
2. Cellular recycling-driven in vivo half-life extension using recombinant albumin fusions tuned for neonatal Fc receptor (FcRn) engagement.
Larsen MT; Rawsthorne H; Schelde KK; Dagnæs-Hansen F; Cameron J; Howard KA
J Control Release; 2018 Oct; 287():132-141. PubMed ID: 30016735
[TBL] [Abstract][Full Text] [Related]
3. Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn
Mester S; Evers M; Meyer S; Nilsen J; Greiff V; Sandlie I; Leusen J; Andersen JT
MAbs; 2021; 13(1):1893888. PubMed ID: 33691596
[TBL] [Abstract][Full Text] [Related]
4. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
5. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.
Oberst MD; Fuhrmann S; Mulgrew K; Amann M; Cheng L; Lutterbuese P; Richman L; Coats S; Baeuerle PA; Hammond SA
MAbs; 2014; 6(6):1571-84. PubMed ID: 25484061
[TBL] [Abstract][Full Text] [Related]
6. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
7. Half-life extension of efficiently produced DARPin serum albumin fusions as a function of FcRn affinity and recycling.
Merten H; Brandl F; Zimmermann M; Schaefer JV; Irpinio L; Sand KMK; Nilsen J; Andersen JT; Zangemeister-Wittke U; Plückthun A
Eur J Pharm Biopharm; 2021 Oct; 167():104-113. PubMed ID: 34303832
[TBL] [Abstract][Full Text] [Related]
8. A new class of recombinant human albumin with multiple surface thiols exhibits stable conjugation and enhanced FcRn binding and blood circulation.
Schelde KK; Nicholls K; Dagnæs-Hansen F; Bunting K; Rawsthorne H; Andersen B; Finnis CJA; Williamson M; Cameron J; Howard KA
J Biol Chem; 2019 Mar; 294(10):3735-3743. PubMed ID: 30602565
[TBL] [Abstract][Full Text] [Related]
9. Half-life-extended recombinant coagulation factor IX-albumin fusion protein is recycled via the FcRn-mediated pathway.
Chia J; Louber J; Glauser I; Taylor S; Bass GT; Dower SK; Gleeson PA; Verhagen AM
J Biol Chem; 2018 Apr; 293(17):6363-6373. PubMed ID: 29523681
[TBL] [Abstract][Full Text] [Related]
10. Full-length recombinant antibodies from
Rashid MH
MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
[TBL] [Abstract][Full Text] [Related]
11. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin.
Müller D; Karle A; Meissburger B; Höfig I; Stork R; Kontermann RE
J Biol Chem; 2007 Apr; 282(17):12650-60. PubMed ID: 17347147
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors.
Wingert S; Reusch U; Knackmuss S; Kluge M; Damrat M; Pahl J; Schniegler-Mattox U; Mueller T; Fucek I; Ellwanger K; Tesar M; Haneke T; Koch J; Treder M; Fischer W; Rajkovic E
MAbs; 2021; 13(1):1950264. PubMed ID: 34325617
[TBL] [Abstract][Full Text] [Related]
13. An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein.
Seijsing J; Lindborg M; Höidén-Guthenberg I; Bönisch H; Guneriusson E; Frejd FY; Abrahmsén L; Ekblad C; Löfblom J; Uhlén M; Gräslund T
Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17110-5. PubMed ID: 25406323
[TBL] [Abstract][Full Text] [Related]
14. Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics.
Andersen JT; Cameron J; Plumridge A; Evans L; Sleep D; Sandlie I
J Biol Chem; 2013 Aug; 288(33):24277-85. PubMed ID: 23818524
[TBL] [Abstract][Full Text] [Related]
15. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein.
Hopp J; Hornig N; Zettlitz KA; Schwarz A; Fuss N; Müller D; Kontermann RE
Protein Eng Des Sel; 2010 Nov; 23(11):827-34. PubMed ID: 20817756
[TBL] [Abstract][Full Text] [Related]
16. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
[TBL] [Abstract][Full Text] [Related]
17. COBRA™: a highly potent conditionally active T cell engager engineered for the treatment of solid tumors.
Panchal A; Seto P; Wall R; Hillier BJ; Zhu Y; Krakow J; Datt A; Pongo E; Bagheri A; Chen TT; Degenhardt JD; Culp PA; Dettling DE; Vinogradova MV; May C; DuBridge RB
MAbs; 2020; 12(1):1792130. PubMed ID: 32684124
[TBL] [Abstract][Full Text] [Related]
18. A Humanized Mouse Model to Study Human Albumin and Albumin Conjugates Pharmacokinetics.
Low BE; Wiles MV
Methods Mol Biol; 2016; 1438():115-22. PubMed ID: 27150087
[TBL] [Abstract][Full Text] [Related]
19. Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity.
Hangiu O; Compte M; Dinesen A; Navarro R; Tapia-Galisteo A; Mandrup OA; Erce-Llamazares A; Lázaro-Gorines R; Nehme-Álvarez D; Domínguez-Alonso C; Harwood SL; Alfonso C; Blanco B; Rubio-Pérez L; Jiménez-Reinoso A; Díez-Alonso L; Blanco FJ; Sanz L; Howard KA; Álvarez-Vallina L
iScience; 2022 Sep; 25(9):104958. PubMed ID: 36072551
[TBL] [Abstract][Full Text] [Related]
20. Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain.
Andersen JT; Pehrson R; Tolmachev V; Daba MB; Abrahmsén L; Ekblad C
J Biol Chem; 2011 Feb; 286(7):5234-41. PubMed ID: 21138843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
